<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00356681</url>
  </required_header>
  <id_info>
    <org_study_id>20050225</org_study_id>
    <secondary_id>CIRG/TORI 010</secondary_id>
    <nct_id>NCT00356681</nct_id>
  </id_info>
  <brief_title>A Study of AMG 706 or Bevacizumab, in Combination With Paclitaxel Chemotherapy, as Treatment for Breast Cancer</brief_title>
  <official_title>A Randomized Phase 2 Trial of Double-Blind, Placebo Controlled AMG 706 in Combination With Paclitaxel, or Open-Label Bevacizumab in Combination With Paclitaxel, as First Line Therapy in Women With HER2 Negative Locally Recurrent or Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if treatment with paclitaxel plus AMG 706 is superior to paclitaxel plus AMG 706
      placebo in subjects with HER2 negative locally recurrent or metastatic breast cancer. Also to
      estimate differences between treatment with paclitaxel plus AMG 706 and paclitaxel plus
      bevacizumab.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Sponsor decision to close study
  </why_stopped>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate, measured radiologically and assessed by an independent review committee.</measure>
    <time_frame>Last patient enrolled + 16 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival, duration of response, clinical benefit rate (percentage of subjects with complete response, partial response or stable disease lasting &gt;24 weeks), overall survival and incidence of adverse events.</measure>
    <time_frame>&gt;24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">282</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Breast Tumors</condition>
  <condition>Breast Cancer</condition>
  <condition>Locally Recurrent and Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Blinded AMG 706 placebo plus paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded AMG 706 plus paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Open-label bevacizumab plus paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 706 placebo</intervention_name>
    <description>Blinded placebo</description>
    <arm_group_label>Arm A Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.</description>
    <arm_group_label>Arm C Comparator</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 706</intervention_name>
    <description>AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.</description>
    <arm_group_label>Arm B Experimental</arm_group_label>
    <other_name>motesanib diphosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.</description>
    <arm_group_label>Arm A Placebo</arm_group_label>
    <arm_group_label>Arm B Experimental</arm_group_label>
    <arm_group_label>Arm C Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed adenocarcinoma of the breast with locally
             recurrent or metastatic disease.

          -  Measurable disease by RECIST guidelines.

          -  Tumor (primary or metastatic) must be HER2 negative.

          -  Adequate organ and hematologic function. Exclusion:

          -  Taxane treatment within 12 months prior to registration.

          -  Prior chemotherapy for locally recurrent or metastatic breast cancer (prior endocrine
             therapy is permitted).

          -  Prior radiation therapy, radiofrequency ablation, percutaneous cryotherapy or hepatic
             chemoembolization on all sites of measurable disease.

          -  Current or prior history of central nervous system metastases.

          -  Peripheral neuropathy â‰¥ grade 2 (CTCAE v3.0) at registration.

          -  History of arterial or venous thrombosis within 1 year prior to registration.

          -  History of bleeding diathesis or bleeding within 14 days of registration.

          -  Uncontrolled hypertension (systolic &gt;145 mmHg; diastolic &gt;85 mmHg).

          -  Clinically significant cardiac disease within 12 months of registration.

          -  Known HIV positive, hepatitis C positive or hepatitis B surface antigen positive.

          -  Prior treatment with VEGFr targeted therapies.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Ireland</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2006</study_first_submitted>
  <study_first_submitted_qc>July 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2006</study_first_posted>
  <disposition_first_submitted>April 16, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>April 16, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">May 6, 2015</disposition_first_posted>
  <last_update_submitted>September 24, 2015</last_update_submitted>
  <last_update_submitted_qc>September 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AMG 706</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Antiangiogenic</keyword>
  <keyword>Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

